Cardiff Oncology, Inc.

Equities

CRDF

US14147L1089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-14 EDT			5-day change	1st Jan Change
2.7 ^USD	-4.59%		-7.85%	+82.43%

05-02	Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024
05-02	Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

CARDIFF ONCOLOGY, INC. : Other Events (form 8-K)

January 31, 2022 at 05:31 pm

Item 8.01 Other Events.

On January 31, 2022, Cardiff Oncology, Inc. issued a press release announcing that on January 31, 2022, non-qualified stock option awards to purchase an aggregate of 55,008 shares of its common stock were granted to one new employee. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Latest news about Cardiff Oncology, Inc.

Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study	04-08	CI
HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating	03-06	MT
Sector Update: Health Care Stocks Rising Late Afternoon	03-01	MT
Sector Update: Health Care	03-01	MT
Cardiff Oncology Shares Jump, Discontinued Cancer Treatment Trial Shows Efficacy	03-01	MT
Piper Sandler Adjusts Price Target on Cardiff Oncology to $7 From $5, Maintains Overweight Rating	03-01	MT
Transcript : Cardiff Oncology, Inc., Q4 2023 Earnings Call, Feb 29, 2024	02-29
Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)	02-29	CI
Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC	02-29	CI
Cardiff Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Transcript : Cardiff Oncology, Inc., Q3 2023 Earnings Call, Nov 02, 2023	11-02
Cardiff Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Top Premarket Gainers	23-09-27	MT
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields	23-09-27	DJ
Cardiff Oncology Reports 'Positive' Results From Onvansertib Monotherapy Trial for Pancreatic, Small Cell Lung Cancers	23-09-26	MT
Transcript : Cardiff Oncology, Inc. - Special Call	23-09-26
Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy	23-09-26	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from S&P Global BMI Index	23-09-18	CI
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
HC Wainwright Adjusts Price Target on Cardiff Oncology to $12 From $13, Maintains Buy Rating	23-08-11	MT
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Sector Update: Health Care Stocks Gaining Late Tuesday	23-08-08	MT
Sector Update: Health Care	23-08-08	MT

Chart Cardiff Oncology, Inc.

Duration

Period

More charts

Company Profile

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Cardiff Oncology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.7 USD

Average target price

9.833 USD

Spread / Average Target

+264.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CARDIFF ONCOLOGY, INC.	+82.43%	121M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research